Sino Biopharmaceutical
Pharmaceutical company that engages in research, development and pharmaceutical products for treating diseases.
Launch date
Employees
Market cap
$8.4b
Enterprise valuation
$7.9b (Public information from Sep 2024)
Share price
HKD3.7
Hong Kong Island Hong Kong (HQ)
Financials
Estimates*
EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 3.0b | 3.4b | 3.6b | 3.3b | 3.7b | 4.1b | 4.5b |
% growth | (2 %) | 14 % | 7 % | (9 %) | 13 % | 11 % | 11 % |
EBITDA | 719m | 647m | 864m | 810m | 978m | 1.0b | 1.1b |
% EBITDA margin | 24 % | 19 % | 24 % | 25 % | 26 % | 26 % | 25 % |
Profit | 346m | 1.8b | 318m | 292m | 431m | 405m | 466m |
% profit margin | 12 % | 54 % | 9 % | 9 % | 12 % | 10 % | 10 % |
EV / revenue | 5.0x | 3.0x | 2.5x | 2.2x | 1.7x | 1.4x | 1.1x |
EV / EBITDA | 20.4x | 15.5x | 10.5x | 8.9x | 6.4x | 5.5x | 4.5x |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
* | N/A | CNY290m Valuation: CNY350m 0.0x EV/LTM Revenues 0.1x EV/LTM EBITDA | Acquisition |
Total Funding | - |
Recent News about Sino Biopharmaceutical
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Sino Biopharmaceutical
Editexited
exited
ACQUISITION by Sino Biopharmaceutical Mar 2021